Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity-Reference-Cited by-同舟云学术

Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity

Published:2016-06-30 Issue:3 Volume:82 Page:683-695
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Aminkeng Folefac¹²,Ross Colin J. D.²³,Rassekh Shahrad R.²⁴,Hwang Soomi⁵,Rieder Michael J.⁶,Bhavsar Amit P.²³^ORCID,Smith Anne²⁷,Sanatani Shubhayan²,Gelmon Karen A.⁸,Bernstein Daniel⁹,Hayden Michael R.¹²¹⁰,Amstutz Ursula²³¹¹,Carleton Bruce C.²⁷,

Affiliation:

1. Centre for Molecular Medicine and Therapeutics, Department of Medical GeneticsUniversity of British Columbia Vancouver BC Canada

2. Child & Family Research InstituteUniversity of British Columbia Vancouver BC Canada

3. Division of Translational Therapeutics, Department of PediatricsUniversity of British Columbia Vancouver BC Canada

4. Division of Pediatric Hematology/Oncology/BMT, Department of PediatricsUniversity of British Columbia Vancouver BC Canada

5. Faculty of Pharmaceutical SciencesUniversity of British Columbia Vancouver BC Canada

6. Department of PediatricsUniversity of Western Ontario London ON Canada

7. Pharmaceutical Outcomes & Policy Innovations ProgrammeBC Children's Hospital Vancouver BC Canada

8. British Columbia Cancer Agency Vancouver BC Canada

9. Department of Pediatrics, Division of CardiologyStanford University Stanford CA USA

10. Translational Laboratory in Genetic Medicine, National University of Singapore and Association for ScienceTechnology and Research (A*STAR) Singapore

11. University Institute of Clinical Chemistry, Inselspital Bern University Hospital and University of Bern Switzerland

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13008

Reference116 articles.

1. AltekruseSFKosaryCL KrapchoM NeymanN AminouR WaldronW et al. eds.SEER Cancer Statistics Review 1975–2007. Bethesda: National Cancer Institute 2010.

2. Anthracycline cardiotoxicity in long-term survivors of childhood cancer

3. Cancer Therapy Evaluation Program – Common Terminology Criteria for Adverse Events – Version 3 2003.

4. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiscale mapping of transcriptomic signatures for cardiotoxic drugs;Nature Communications;2024-09-11

2. Cardiovascular Pharmacogenetics: From Discovery of Genetic Association to Clinical Adoption of Derived Test;Pharmacological Reviews;2024-08-09

3. Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines;Children;2024-07-22

4. Population-scale variability of the human UDP-glycosyltransferase gene family;Journal of Genetics and Genomics;2024-07

5. StemRegenin-1 Reverses Drug Resistance of MCF-7/ADR Cells via AhR/ABC Transports and AhR/UGTs Pathways;Current Proteomics;2024-06